Influence of diabetes and type of hypertension on response to antihypertensive treatment

被引:79
作者
Brown, MJ
Castaigne, A
de Leeuw, PW
Mancia, G
Palmer, CR
Rosenthal, T
Ruilope, LM
机构
[1] Univ Cambridge, Clin Pharmacol Unit, Cambridge CB2 2QQ, England
[2] Univ Cambridge, Ctr Appl Med Stat, Cambridge CB2 2QQ, England
[3] Univ Paris, Hop Henri Mondor, Serv Cardiol, Paris, France
[4] Univ Maastricht, Maastricht, Netherlands
[5] Univ Milan, Cattedra Med Interna, I-20122 Milan, Italy
[6] Tel Aviv Univ, Chaim Sheba Med Ctr, Hypertens Unit, IL-69978 Tel Aviv, Israel
[7] Univ Madrid, Hosp 12 Octubre, Dept Nephrol, Madrid, Spain
关键词
cardiovascular diseases; diabetes mellitus; random allocation; antihypertensive therapy; calcium channel blockers; diuretics;
D O I
10.1161/01.HYP.35.5.1038
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
The aim of our investigation was to determine whether the presence of additional risk factors or type of hypertension (diastolic or isolated systolic) influences blood pressure (BP) response to treatment. The International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT) study is a double-blinded outcome comparison of calcium channel blockade with diuretics in high-risk patients aged 55 to 80 years. Dynamic randomization between nifedipine once daily and hydrochlorothiazide/amiloride was performed to ensure that approximately equal numbers of patients in the 2 groups had each of the major cardiovascular risk factors. Patients with isolated systolic hypertension were also separately randomized. Atenolol or enalapril was the mandatory second-line drug. In 5669 patients who completed the Is-week titration, BP fell from 172+/-15/99+/-9 mm Pig (mean+/-SD) while receiving placebo to 139+/-12/82+/-7 mm Hg. Twenty-six percent of patients required 2 drugs, and 4% required 3 drugs. Patients with diabetes were the most resistant to treatment, requiring second and third drugs 40% and 100% more frequently than patients without diabetes and achieving marginally the highest final BP, for any risk group, of 141+/-13/82+/-8 mm Hg. Age, smoking, gender, hypercholesterolemia, left ventricular hypertrophy, and existing atherosclerosis had little (<1 mm Hg) or no influence on BP at the end of titration, but all except smoking slightly reduced the initial response of either systolic or diastolic BP. Patients with isolated systolic hypertension were slightly more responsive than average to treatment. Our findings suggest that in patients at high absolute risk of cardiovascular complications from hypertension, the risk factors themselves do not prevent the recommended BP targets from being achieved.
引用
收藏
页码:1038 / 1042
页数:5
相关论文
共 17 条
[1]   Distribution and determinants of cardiovascular events during 20 years of successful antihypertensive treatment [J].
Alderman, MH ;
Cohen, H ;
Madhavan, S .
JOURNAL OF HYPERTENSION, 1998, 16 (06) :761-769
[2]   Survival in treated hypertension: follow up study after two decades [J].
Andersson, OK ;
Almgren, T ;
Persson, B ;
Samuelsson, O ;
Hedner, T ;
Wilhelmsen, L .
BMJ-BRITISH MEDICAL JOURNAL, 1998, 317 (7152) :167-171
[3]  
Brown MJ, 1998, J HYPERTENS, V16, P2113
[4]  
Brown MJ, 1996, J HUM HYPERTENS, V10, pS157
[5]  
Chalmers J, 1999, J HYPERTENS, V17, P151
[6]  
GILL JS, 1985, LANCET, V1, P567
[7]  
GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97
[8]   Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension:: the Captopril Prevention Project (CAPPP) randomised trial [J].
Hansson, L ;
Lindholm, LH ;
Niskanen, L ;
Lanke, J ;
Hedner, T ;
Niklason, A ;
Luomanmäki, K ;
Dahlöf, B ;
de Faire, U ;
Mörlin, C ;
Karlberg, BE ;
Wester, PO ;
Björck, JE .
LANCET, 1999, 353 (9153) :611-616
[9]   Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:: principal results of the hypertension optimal treatment (HOT) randomised trial [J].
Hansson, L ;
Zanchetti, A ;
Carruthers, SG ;
Dahlöf, B ;
Elmfeldt, D ;
Julius, S ;
Ménard, J ;
Rahn, KH ;
Wedel, H ;
Westerling, S .
LANCET, 1998, 351 (9118) :1755-1762
[10]   SINGLE-DRUG THERAPY FOR HYPERTENSION IN MEN - A COMPARISON OF 6 ANTIHYPERTENSIVE AGENTS WITH PLACEBO [J].
MATERSON, BJ ;
REDA, DJ ;
CUSHMAN, WC ;
MASSIE, BM ;
FREIS, ED ;
KOCHAR, MS ;
HAMBURGER, RJ ;
FYE, C ;
LAKSHMAN, R ;
GOTTDIENER, J ;
RAMIREZ, EA ;
HENDERSON, WG .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (13) :914-921